Loading
Dogwood Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Pridgen William, was filed 22 Aug 2023.
Dogwood Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Dogwood Therapeutics, Inc. as filed with SEC (Form 4), a company from the Health Care sector. 1 insider has disclosed 2 filings since 24 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Dogwood Therapeutics, Inc. shares on the open market in the past twelve months.
Across the 3,169 companies tracked on its exchange, the median is 24 filings; at 2 filings, this issuer sits below that mark. Since 2020, the database holds 24 purchases and 1 sale by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -34.3 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€454,492
24 ops. · all time
Sell Volume
€444
1 ops. · all time
Since the insiders bought
- -82.5%Entry US$30.00 · Close at T+365 US$5.25
- -85.2%Entry US$32.00 · Close at T+365 US$4.75
- -70.0%Entry US$101.00 · Close at T+365 US$30.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.21
Analyst consensus
3 analysts1.50/5
US$12.00Target US$14.00(+1057%)US$15.00
Income statement
EBITDA-US$28M
Net income-US$34.3M0.0% margin
Valuation
PER (trailing)0.6x
P/Book0.6x
Beta1.94
Balance sheet & cash
Market capUS$41.1M
Total debtUS$162.6k
Free Cash Flow-US$15.6M
Debt / Equity0%
Profitability & ownership
ROE-47.8%
ROA-20.8%
% insiders72.6%
% institutions11.5%
Last declaration on 25 November 2025
Declarations30 total
2,842,638 sharesCommon StockSEC:0001104659-25-116066:1
21,610,950 sharesCommon StockSEC:0001104659-25-116066:0
15,335 shares@ US$1.303710.7% of flowCommon StockSEC:0001415889-23-012474:0
Canonical exit: 19 Nov 2023 (T+90)
25,000 shares@ US$1.249833.8% of flowCommon StockSEC:0001415889-23-012375:0
Canonical exit: 15 Nov 2023 (T+90)
1,800 shares@ US$0.25913.5% of flowCommon StockSEC:0001415889-22-012370:0
2,000 shares@ US$4.575100.0% of flowCommon StockSEC:0001415889-22-005575:0
Canonical exit: 21 Aug 2022 (T+90)
7,500 shares@ US$4.5237.4% of flowCommon StockSEC:0001415889-22-005567:0
Canonical exit: 21 Aug 2022 (T+90)
500 shares@ US$4.52517.0% of flowCommon StockSEC:0001415889-22-005275:0
Canonical exit: 16 Aug 2022 (T+90)
241 shares@ US$4.500.6% of flowCommon StockSEC:0001415889-22-005272:0
Canonical exit: 16 Aug 2022 (T+90)
13,450 shares@ US$4.380232.7% of flowCommon StockSEC:0001415889-22-005214:0
Canonical exit: 15 Aug 2022 (T+90)
600 shares@ US$4.94081.6% of flowCommon StockSEC:0001415889-22-003465:0
Canonical exit: 27 Jun 2022 (T+90)
2,197 shares@ US$5.46276.4% of flowCommon StockSEC:0001415889-22-003314:0
Canonical exit: 21 Jun 2022 (T+90)
4,180 shares@ US$5.980313.0% of flowCommon StockSEC:0001415889-22-000846:0
Canonical exit: 27 Apr 2022 (T+90)
4,000 shares@ US$5.896100.0% of flowCommon StockSEC:0001415889-22-000462:0
Canonical exit: 7 Apr 2022 (T+90)
1,800 shares@ US$5.7271.6% of flowCommon StockSEC:0001415889-22-000447:0
Canonical exit: 6 Apr 2022 (T+90)
5,000 shares@ US$5.795100.0% of flowCommon StockSEC:0001415889-22-000350:0
Canonical exit: 4 Apr 2022 (T+90)
2,215 shares@ US$5.43296.2% of flowCommon StockSEC:0001415889-22-000167:0
Canonical exit: 3 Apr 2022 (T+90)
1,000 shares@ US$5.65100.0% of flowCommon StockSEC:0001415889-22-000165:0
Canonical exit: 4 Apr 2022 (T+90)
200 shares@ US$5.7257.9% of flowCommon StockSEC:0001415889-21-006204:0
Canonical exit: 23 Mar 2022 (T+90)
5,000 shares@ US$5.52328.8% of flowCommon StockSEC:0001415889-21-006172:0
Canonical exit: 21 Mar 2022 (T+90)
8,827 shares@ US$5.664125.9% of flowCommon StockSEC:0001415889-21-006174:0
Canonical exit: 21 Mar 2022 (T+90)
942 shares@ US$6.3173.0% of flowCommon StockSEC:0001415889-21-003569:0
Canonical exit: 5 Oct 2021 (T+90)
382 shares@ US$6.361.2% of flowCommon StockSEC:0001104659-21-047486:0
Canonical exit: 5 Jul 2021 (T+90)
15,675 shares@ US$6.1747.1% of flowCommon StockSEC:0001104659-21-047069:0
Canonical exit: 4 Jul 2021 (T+90)
801 shares@ US$7.802.4% of flowCommon StockSEC:0001104659-21-010386:0
25 of 30 declarations
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. is a company focused on developing innovative treatments for neurological diseases. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
